Bladder Cancer

Urothelial carcinoma of the bladder — NMIBC versus MIBC, BCG intravesical immunotherapy, radical cystectomy, and neoadjuvant chemotherapy

Key Points

• Bladder cancer is the 4th most common cancer in American men; ~83,190 new cases and ~16,840 deaths were projected in the US in 2024.
• ~90% are urothelial (transitional cell) carcinomas; cigarette smoking is the leading risk factor, accounting for ~50% of cases.
• ~75% present as non-muscle-invasive bladder cancer (NMIBC — stages Ta, T1, CIS); ~25% as muscle-invasive (MIBC — stage T2+).
• NMIBC is treated with TURBT ± intravesical BCG; BCG-unresponsive high-risk NMIBC can now be treated with pembrolizumab (FDA approved).
• MIBC treatment standard: neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy — neoadjuvant chemo improves overall survival ~5–8%.
• Nivolumab adjuvant therapy after radical cystectomy (CheckMate 274) is approved for high-risk pathologic stage ≥pT3 or N+ disease.
• Trimodality therapy (maximal TURBT + concurrent chemoradiation) is the primary bladder-sparing alternative to radical cystectomy.

Epidemiology & Incidence

Bladder cancer is the fourth most common cancer in men and eleventh in women in the United States. In 2024, approximately 83,190 new cases and 16,840 deaths were projected. The male-to-female ratio is approximately 3.5:1, though women are often diagnosed at more advanced stages, possibly due to diagnostic delay. The median age at diagnosis is 73 years, making bladder cancer predominantly a disease of older adults. The vast majority (~90%) of bladder cancers are urothelial carcinomas (formerly called transitional cell carcinoma), arising from the urothelial lining of the bladder. Less common…

Risk Factors & Molecular Biology

Cigarette smoking is the most important risk factor, accounting for approximately 50% of bladder cancer cases. The risk is proportional to pack-year history and duration; former smokers retain elevated risk for decades. Occupational exposure to aromatic amines (β-naphthylamine, benzidine) is the second major risk factor — historically relevant in rubber, dye, leather, and printing industries. Other risk factors include: cyclophosphamide chemotherapy (acrolein metabolite), pelvic radiation, chronic urinary tract infections/catheterization, aristolochic acid nephropathy (herbal medicines), and…

Clinical Presentation & Diagnosis

Bladder cancer most commonly presents with hematuria: • Gross hematuria (visible): Present in ~85% of bladder cancer patients; typically painless and intermittent. ANY episode of painless gross hematuria in an adult warrants urologic evaluation — it is bladder cancer until proven otherwise. • Microscopic hematuria: Defined as ≥3 RBC/HPF on two of three properly collected specimens; lower sensitivity and specificity than gross hematuria. • Irritative voiding symptoms: Urgency, frequency, dysuria — more characteristic of carcinoma in situ (CIS) and muscle-invasive disease; may mimic UTI or…

Staging & NMIBC Treatment

Bladder cancer is staged using the AJCC TNM system: • Ta: Non-invasive papillary carcinoma (confined to mucosa) • Tis (CIS): Flat, high-grade carcinoma in situ — not T0 but aggressive biology • T1: Invasion of lamina propria (subepithelial connective tissue) • T2a/b: Invasion of superficial/deep muscularis propria • T3a/b: Microscopic/macroscopic perivesical fat invasion • T4a: Invades prostate stroma, seminal vesicles, uterus, or vagina • T4b: Invades pelvic/abdominal wall NMIBC (Ta, T1, CIS — ~75% of cases at diagnosis): All NMIBC is treated with complete TURBT. Risk stratification drives…

MIBC & Advanced Treatment

Muscle-invasive bladder cancer (MIBC — T2–T4, N0–N1, M0) requires curative-intent multimodal treatment: Neoadjuvant chemotherapy (NAC): • Cisplatin-based NAC before radical cystectomy improves overall survival ~5–8% (SWOG 8710, BA06 30894). • Regimens: Dose-dense MVAC (methotrexate + vinblastine + doxorubicin + cisplatin — preferred) or gemcitabine + cisplatin (GC). • Pathologic downstaging (pT0/Tis/Ta at cystectomy) after NAC is associated with markedly improved 5-year OS (~85%). Radical cystectomy (RC): • Gold standard for MIBC; includes removal of bladder, prostate/seminal vesicles (men)…